Straumann stock advances on 2025 revenue growth and margin gains

Straumann (CH0012280076) stock is anchored by 2025 revenue of CHF 1,986.6 million and a 2025 core EBIT margin of 27.8%, while the company also reported 2025 sales growth of 13.7% in local currencies. Those figures frame the investment case more clearly than any short-term market noise.

Revenue up 13.7%

Straumann reported 2025 revenue of CHF 1,986.6 million, compared with CHF 1,876.1 million in 2024, according to the company’s investor relations materials. The local-currency sales increase of 13.7% shows that volume and mix still matter more than a single trading session.

The same reporting set puts 2025 core EBIT at CHF 552.0 million, up from CHF 489.3 million a year earlier. The core EBIT margin rose to 27.8% from 26.1%, a 1.7 percentage point improvement that signals better operating leverage.

Margin reaches 27.8%

For investors, the margin is the cleaner signal. Revenue growth of CHF 110.5 million year over year and EBIT growth of CHF 62.7 million suggest that Straumann kept more of each additional franc than in 2024.

The company’s latest annual reporting also gives a fuller view of earnings quality. Core net profit reached CHF 421.6 million in 2025, compared with CHF 372.7 million in 2024, which is a year-over-year increase of CHF 48.9 million.

Dental implants remain central

Straumann’s core dental implant and orthodontic portfolio remains the commercial engine behind those numbers. The group’s latest reporting shows that premium implant demand, digital workflows, and adjacent restorative products continue to support both revenue and margin expansion.

The product mix matters because it ties recurring clinical demand to higher-value services and systems. That combination helps explain why a 13.7% local-currency sales increase translated into a 27.8% core EBIT margin rather than just top-line growth.

2025 sets the base

The 2025 annual figures now define the base case for any valuation debate. Revenue of CHF 1,986.6 million, core EBIT of CHF 552.0 million, and core net profit of CHF 421.6 million give the market three hard reference points for assessing 2026 execution.

Those numbers matter because Straumann is still a high-margin medical technology group rather than a simple volume story. When a company lifts both sales and profitability in the same year, investors tend to focus on whether that pace can be repeated rather than on the headline alone.

Straumann system products

The Straumann implant and restorative system is the product family that best explains the latest results. It sits at the center of the group’s premium dentistry platform and links treatment demand with digital and restorative add-ons.

Shares near the Swiss market

Straumann stock remains a Swiss healthcare value story shaped by 2025 operating results rather than a single daily price print. The latest yearly figures show CHF 1,986.6 million in revenue, CHF 552.0 million in core EBIT, and CHF 421.6 million in core net profit, all of which are now the key anchors for the next reporting cycle.